Lulizumab pegol
Jump to navigation
Jump to search
Monoclonal antibody | |
---|---|
Type | ? |
Source | Humanized |
Target | glycoprotein CD28 |
Clinical data | |
Other names | BMS-931699 |
ATC code |
|
Identifiers | |
CAS Number | |
IUPHAR/BPS | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C552H859N149O164S4 |
Molar mass | 12335.06 g·mol−1 |
Lulizumab pegol (INN;[1] development code BMS-931699) is a monoclonal antibody designed for the treatment of autoimmune diseases.[2]
This drug was developed by Bristol-Myers Squibb.
References
Categories:
- Drugs not assigned an ATC code
- Chemicals that do not have a ChemSpider ID assigned
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a monoclonal antibody
- Monoclonal antibodies
- Drugs developed by Bristol Myers Squibb
- All stub articles
- Monoclonal antibody stubs